CytomX Therapeutics, Inc.
Company Stats
- Market Cap
- $592.7M
- as of Sep 30, 2026
- Shares Outstanding
- 217.9M
- Free Float
- 98.9%
Income Statement
- Revenue
- $76.2M
- Operating Income
- -$22.4M
- Net Income
- -$17.4M
- EBITDA
- -$21.2M
- Revenue Growth, 3Y
- 12.8%
- FCF Margin, 3Y Avg
- -72.8%
- FCF Margin, Worst Year
- -99.5%
Cash Flow
- Free Cash Flow
- -$75.8M
- FCF Yield
- -12.8%
- Owner FCF Yield
- -13.9%
Balance Sheet
- Cash & Equivalents
- $12.7M
Returns & Capital
- SBC, 3Y Avg
- $7.5M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $76.2M | -$75.8M | -99.5% |
| FY2024 | $138.1M | -$86.5M | -62.7% |
| FY2023 | $101.2M | -$56.9M | -56.2% |
| FY2022 | $53.2M | -$112.5M | -211.7% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 30, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back